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Ageing  is  accompanied  by many  visible  characteristics.  Other  biological  and  physiological  markers  are  also
well-described  e.g.  loss  of  circulating  sex  hormones  and  increased  inﬂammatory  cytokines.  Biomarkers
for healthy  ageing  studies  are  presently  predicated  on existing  knowledge  of  ageing  traits.  The  increasing
availability  of data-intensive  methods  enables  deep-analysis  of  biological  samples  for  novel biomark-
ers.  We  have  adopted  two  discrete  approaches  in MARK-AGE  Work  Package  7 for  biomarker  discovery;
(1)  microarray  analyses  and/or  proteomics  in cell  systems  e.g.  endothelial  progenitor  cells  or  T cell
ageing  including  a stress  model;  and  (2) investigation  of  cellular  material  and  plasma  directly  from
tightly-deﬁned  proband  subsets  of different  ages  using  proteomic,  transcriptomic  and  miR array.  The
ﬁrst approach  provided  longitudinal  insight  into  endothelial  progenitor  and  T  cell ageing.
This review  describes  the  strategy  and  use  of hypothesis-free,  data-intensive  approaches  to  explore
ndothelial progenitor cells cellular  proteins,  miR,  mRNA  and plasma  proteins  as healthy  ageing  biomarkers,  using  ageing  models
and  directly  within  samples  from  adults  of different  ages.  It considers  the challenges  associated  with
integrating  multiple  models  and  pilot  studies  as  rational  biomarkers  for  a large  cohort  study.  From  this
approach,  a number  of high-throughput  methods  were  developed  to  evaluate  novel, putative  biomarkers
of ageing  in the  MARK-AGE  cohort.
Crown Copyright  © 2015  Published  by  Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/4.0/).
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. Introduction
.1. Biomarkers of ageing discovery
We  have been aware of the normal age-associated changes in
uman physiology, for example loss of arterial elasticity, since the
ays of the ancient Greeks; these changes may  in some individuals
redispose to cardiovascular events for which clinical intervention
s essential (Lee and Oh, 2010). This sort of epidemiological evi-
ence, of age-associated characteristics and diseases, has provided
he foundation for creating hypotheses about the ageing process
Jacob et al., 2013). For example, protein oxidation has been impli-
ated in increased crosslinking of the extracellular matrix with age
nd which contributes to skin wrinkling and poor vascular tone,
either of which normally demand an intervention for survival of
he ageing organism (Baraibar et al., 2013; Ratnayake et al., 2013).
ncreased oxidative DNA damage in short-lived animals provides
urther support for a sub-category of the “damage” or “error the-
ry of ageing” (Sastre et al., 2000; Barja, 2013). Other observations
n the physiology of ageing include an increase in the appear-
nce of senescent cells; this observation is one of several used to
nform the “programmed theory of ageing” (Kirkwood and Melov,
011; van Deursen, 2014). From such theories, a number of ageing-
iomarkers have been proposed and investigated, many within
he MARK-AGE project. Importantly, ageing is a normal process of
evelopment and is not inherently a disease requiring treatment.
herefore, by understanding and being able to deﬁne normal age-
ng better, we may  also be better placed to predict those people
hose health is deviating from normal age-associated change and
ho are therefore are at increased risk for age-associated disease.
ypothesis-driven approaches have been commonplace for scien-
ists over centuries, however, the advent of high data intensity
pproaches has fuelled the opportunity to identify novel biomark-
rs and possibly also develop new hypotheses about ageing.
. Rationale for adopting high data-intensity,
ypothesis-generating methods
Biomedicine, as with all areas of biology, has undergone a rapid
hange in the last 15 years through the development of techno-
ogically advanced methods providing large datasets. We  can now
uestion gene expression patterns simultaneously, the proﬁle of
egulatory microRNA expression, mRNA and the study of protein
orms, their frequency and location or interactions at a particular
oment in time, offering unprecedented insight into many aspects
f human biology. Developing large scale datasets, e.g. of biolog-
cal ageing in the case of MARK-AGE, provides opportunities for
iscovering hitherto unrecognised biomarkers and can also offer
ncreased understanding of the ageing process, generating new
ypotheses in silico. These biomarkers can then be tested through
he associated development of high throughput screening meth-
ds such as qPCR, ELISA or ﬂow cytometry for proteins. Here, we
escribe the approaches, challenges and validation of methods that
ave been applied in the discovery of novel putative biomarkers
f ageing. The data arising from the discovery process has been
ntroduced into the larger MARK-AGE dataset for statistical evalu-
tion and will be published elsewhere. All tissues are used here in
iomarker discovery (T cells, circulating endothelial cells, plasma,
eripheral blood mononuclear cells) are available from a normally
ollected human blood sample. It is not anticipated that any new
iomarkers of healthy ageing which are discovered would be con-
istent between different tissues and indeed the differences may
rovide further insight into healthy ageing.nd Development 151 (2015) 114–121 115
3. Data-intensive methods in ageing biomarker discovery
The sensitivity of mRNA and miR  analysis afforded by their rel-
atively simple ampliﬁcation together with the immense capability
for data mining, has contributed to their popularity in biomarker
discovery. Microarrays are typically used to identify new tar-
gets in a low or medium throughput scale. After identiﬁcation of
speciﬁc mRNA or miRNAs as biomarkers, real-time PCR is used
for validation and high throughput application. Microarray plat-
forms enable the comparison of thousands of genes expressed
in a cell at any given time which are simultaneously monitored;
they have been applied to study the effects of development and
ageing on gene expression. However, the variation in gene expres-
sion changes with age, probably due to declining transcriptional
efﬁciency during ageing remains a problem (de Magalhaes et al.,
2009).
Microarray has been used to study healthy ageing-related
changes in gene expression in a several studies since the concept
of MARK-AGE was developed (ElSharawy et al., 2012; Nakamura
et al., 2012; Lazuardi et al., 2009; Uehara et al., 2006). These stud-
ies have largely been based on cross-sectional cohorts. Varying
approaches have been adopted previously for the use of microar-
ray in biomarker discovery including a pooling approach, where
samples from patients are pooled and compared to controls. This
offers advantages in terms of normalizing outliers but correspond-
ingly restricts the data that can be generated from the system
(Rudolf et al., 2013). The comparative nature of the analyses also
presents a problem when samples are blinded as was  the case
during MARK-AGE; to overcome this we adopted two different
approaches. First, single-blinded analysis was  undertaken after the
sample codes were broken by the biobank, so enabling leukocytes
to be pooled for miR  analysis from multiple donors within a given
decile of years of age. Second, a subset of donors was recruited to
serve as a source of larger cell numbers of known ages for compar-
ative proﬁling at rest and under hyperoxic stress which is known
to induce senescence. This approach allows us to follow longitudi-
nal changes in CD4+ T cells that have been exposed to controlled
“ageing”.
A range of proteomic approaches are available to investigate
the expressed proteome. These include one-dimensional and two-
dimensional polyacrylamide gel electrophoresis with options for
speciﬁc labelling using 2D-DIGE to enable simultaneous sample
separation; gel-free high approaches are also adopted such as
isotope-coded afﬁnity tag ICAT; SILAC; isobaric tagging for relative
and absolute quantitation (iTRAQ); and shotgun proteomics which
is proving increasingly popular in recent times owing to the high
resolving power for complex samples through innovations in mass
spectrometry hardware and methods (Nikolov et al., 2012). MARK-
AGE began in 2008 and use of 2DE with LC–MS was  commonplace at
that time and so was  adopted here. The article by Capri et al. (Capri
et al., 2015) in this edition, has reviewed the few proteomic age-
ing biomarker studies to date. These include a differential plasma
protein pattern in subjects that associates with amyloid deposition
in the brain; a differential expression of ApoE and antioxidant pro-
teins was  observed in the plasma of 10 japanese supercentenarians;
and our own  work has shown age-related changes to the transfer-
rin glycoform (Dunston et al., 2012; Thambisetty et al., 2010; Miura
et al., 2011).
Two  different proteomic strategies were explored as sources of
putative ageing biomarkers in the MARK-AGE project; (1) com-
paring the proteomes of a small healthy population of younger
and older adults, which was carefully controlled for health status;
(2) exploring endothelial markers identiﬁed during PROTEOMAGE
by ﬁshing with antibodies. The workﬂow is illustrated in Fig. 1
and the approaches used are described in detail in Section 3
below.
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. MARK-AGE approaches
.1. Proteomic identiﬁcation of biomarkers in plasma and on the
ell surface using two older and younger healthy male comparator
ubpopulations
Age-related changes can arise in intracellular, cell surface and
xtracellular proteins. Changes in speciﬁc protein concentration,
ocalisation and post-translational modiﬁcation are commonly
eported across a range of physiological systems. For example,
ncorrect protein secretion patterns by retinal pigment epithelial
ells has been associated with the development of age-related
acular degeneration possibly due to uncontrolled trafﬁcking
Kay et al., 2013). In the ageing immune system, re-expression
f CD45RA on the surface of senescent memory T cell accompa-
ies their reactivation (Di Mitri et al., 2011); and accumulation
f an intracellular domain of amyloid precursor protein has been
bserved in ageing neurones due to alterations in proteolytic pro-
essing (Zhang et al., 2012). Alongside, the age-associated changes
n protein localisation, the pattern of post-translational protein
odiﬁcations (PTMs) is also inﬂuenced during ageing. Increased
biquitination of cellular proteins has been described as a result
f impaired proteasomal degradation and in tissue, the collagen
atrix shows evidence of increased advanced glycation endprod-
able 1
emographics of subjects who donated plasma samples for comparative 2DE proteomics
Young adult(n  = 10) 
Mean age 21.4 ± 1.5 years 
BMI  22.5 ± 2.4 
LDL  (mM) 3.82 ± 0.65 
HDL  (mg/dL) 54.4 ± 35 
Blood  pressure(diastolic) mm/Hg 119 ± 9.7 
Blood  pressure (systolic) mm/Hg 75 ± 8.2 kers of ageing by high data methods.
uct formation (Scharf et al., 2013). The greatest oxidative changes
to proteins are expected in the matrix where protein turnover is
low. Indeed non-invasive methods of analysing skin pigment due
to advanced glycation end-products are applied to measure age-
ing (Scharf et al., 2013). The ageing proteome is diverse and offers a
rich source of potential biomarkers that may  be uncovered through
unbiased proteomic analysis using a 2DE and LC–MS approach. 2DE
not only identiﬁes proteins that have either increased or decreased
in concentration within a speciﬁc biological ﬂuid or tissue at a given
time but can also identify spots moving in 2D location. This may  be
due to PTMs that cause an alteration in the pI or mass of a pro-
tein isoform. PTMs that confer a charge to a protein are most likely
to cause an alteration in spot location on a 2D gel and commonly
include phosphorylation (Zhu et al., 2005) and the presence of N-
acetyl neuraminic acid (NANA also known as sialic acid) residues
(Barrabés et al., 2010).
Our initial approach focussed on the plasma proteome from
healthy young men  (mean age = 21.4 ± 1.5 years) and healthy mid-
life men  (mean age = 57.0 ± 1.6 years). Their characteristics are
shown in Table 1.We  identiﬁed twelve spots including transferrin, complement
C3b and transthyretin that were quantitatively different between
the age groups. Transferrin spots showed an acidic shift in older
males (Dunston et al., 2012) which was  due to loss of sialic acid.
.
Mid-life adult(n  = 10)
57.0 ± 1.6 years P = <0.0001
25.4 ± 2.7 NS
4.75 ± 0.6 NS
62.0 ± 3.5 NS
122 ± 7.5 NS
85 ± 10.3 NS
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 high throughput lectin based enzyme linked assay was devel-
ped to detect the galactosylation status of transferrin as a putative
iomarker of ageing (Dunston et al., 2012) and the signiﬁcant differ-
nce in spot intensity by the 2DE LC–MS approach based on pooled
amples, was conﬁrmed in in individual plasma samples by ELLA.
sing this ELLA methodology in the MARK-AGE cohort, asialyla-
ion was analysed in excess in 2500 plasma samples. Coefﬁcients
f variation between assays were <10% and around 50 samples were
nalysed per day. These data will be reported in relation to other
ARK-AGE data.
Compared to the plasma, a more diverse, and therefore poten-
ially richer source of available biomarkers arises within and on the
urface of circulating leukocytes. Progressive decline in immune
efence appear to contribute to impaired resistance to infection
nd reduced tumour surveillance over neoplastic lesions in older
dults (Castle, 2000; Lang et al., 2013). However, crude proteomic
nalysis of total leukocyte populations for age-related biomarkers
s likely to be confounded by age-related changes in speciﬁc subset
requency. Therefore, to reduce this risk and to retain focus on cells
hich decline functionally with age, CD4+ T cells were selected
or further analysis. Previous reports have suggested a shift in the
ytokine proﬁle secreted from T cells during ageing so contributing
o changes in the circulating plasma protein pool, but membrane
roteins have not been investigated in detail. Taking forward this
utative, novel source of ageing biomarkers, membrane markers
n circulating cells are attractive targets to identify since they can
e easily analysed by high throughput approaches such as ﬂow
ytometry and require low sample volumes.
To identify reliable immune cell aging markers in an hypothesis-
ree approach, in Work Package 7 we adopted a membrane
nrichment approach of the CD4+ T cell membrane proteome (puri-
ed by cell surface labelling using Sulfo-NHS-SS-Biotin reagent)
rom young (n = 9, 20–25y) and mid-life male (n = 10; 50–70y)
roups. This approach has been detailed and successfully applied
lsewhere (Carilho Torrao et al., 2013). The requirement to isolate T
ells from subset of healthy subjects was because of the low number
f cells that could be isolated from MARK-AGE probands donating
o the biobank; it was not possible to achieve proteomic analysis
ased on 2D-DIGE and mass spectrometry following isolation of
D4+ cells from MARK-AGE donors. However, collection of blood
amples from an independent subset of volunteers, followed by
DE separation yielded several membrane protein spots with age-
ependent density differences (p < 0.05 and >1.4 fold change) which
ere identiﬁed by LC–MS/MS.
A ﬂow cytometric protocol was established for determining
xpression of target proteins identiﬁed by proteomics on the sur-
ace of CD4+ T cells. Colour compensation was applied was  robust
ith less than 0.5% drift between days. Biological controls, were
ncluded in each batch to check reproducibility of the analysis. The
etween and within batch CV of our analysis based on the analysis
f >10 biological control samples was 18% and 8% for the two  mark-
rs selected for study and this is suitable for a clinical chemistry
nalytical method which would typically show inter- and intra-
atch CV of less than 20% and 10% respectively. Although we  found
ome difﬁculties in assessing about 10–15% of the samples, due to
ebris, we were able to obtain clear and distinctive peaks for CD4+
opulation for 85–90% of the samples. These data will be reported
n relation to other MARK-AGE data.
.2. Recombinant antibody technology as a tool to explore
ndothelial ageing biomarkersA functional vascular system is vital for all organs of our body;
owever a full understanding is hampered by the heterogeneous
ature of the system. Within our human body cellular complex-
ty is a general theme in seemingly identical cells. Individual cellsnd Development 151 (2015) 114–121 117
may  respond differently to external stimuli, thereby giving rise to
functional distinct cells, examples of this being the various subpop-
ulation of endothelial progenitor cells (EPCs) which circulate in the
blood. This population has been shown to home to particular sites
of vascular injury or insult, depending on the age and functionality
of the EPCs and the external stimuli, the EPCs will secrete differ-
ent factors which may  aid in e.g. vascular regeneration (Estes et al.,
2010; Denizot and Nathan, 2010). Another example is the pericyte,
which has been shown to regulate blood ﬂow in the microvasular
system of e.g. the brain (Jespersen and Ostergaard, 2012). Although
less studied, if a few of the pericytes surrounding the vessels start to
be senescent, this could have marked effect on local mechanotrans-
duction and hence oxygenation of tissue. Based on the above it is
clear that single cell analysis and high throughput technologies are
needed to gain further insight into the complexity (Sørensen and
Kristensen, 2011). Today many of the technologies used, e.g. in the
proteomics ﬁeld, suffer from a sensitivity problem demanding that
millions of cells to be analysed together. This will result in an aver-
age picture is obtained of the functional states. Such an approach
will miss out on the inﬂuence of the single or few ageing cells, which
may  exert global changes on the body.
Allowing single cell proteomic analysis, a novel methodology
was developed, based on recombinant antibody technology, which
allow identiﬁcation of biomarkers on single cells in a heterogeneous
population (Sørensen and Kristensen, 2011). Antibody phage dis-
play relies on genetic engineering of antibodies in bacteriophages.
Subsequent ligation of the variable heavy and light PCR products
into a phage display vectors is followed by repeated rounds of
antigen-guided selection and phage propagation. Monoclonal anti-
bodies of virtually any speciﬁcity can be selected for and produced
semi-synthetically. By performing selection using large diversity
antibody libraries (Mandrup et al., 2013) (more than 108 differ-
ent antibodies) were presented as genetic packages on the surface
of ﬁlamentous bacteriophage. Using this approach, it was  possi-
ble to isolate antibodies which bind sub-populations of cells, such
as senescent cells. The technology has been optimised, allowing
selection of antibodies binding speciﬁcally to one identiﬁed cell
in a heterogenous population (Sørensen and Kristensen, 2011;
Mandrup et al., 2013). Following identiﬁcation of the cognate anti-
gens recognised by the isolated antibodies, it has been possible to
test if the identiﬁed antigens qualify as biomarkers of ageing, as we
have done in the MARK-AGE project. Within MARK-AGE we have in
particular focused on an antigen, which was  identiﬁed in a FP6 EU
supported project Proteomage and which were identiﬁed by selec-
tion of recombinant antibodies on human endothelial cells allowed
to age in culture (Boisen et al., 2010; Boisen and Kristensen, 2010).
The analysis of plasma for proteins which have been secreted
by endothelial cells as biomarkers of ageing was undertaken using
4 antibodies isolated using Phage Display technology for applica-
tion in ELISA. In addition a panel of antibodies recognising T cells
was being analysed for their potential to discriminate ageing T cells
using ﬂow cytometric analysis.
4.3. Culture of T cells under physiological and atmospheric
oxygen conditions
Atmospheric oxygen pressure generates oxidant stresses on
human and murine cells cultivated in vitro and non-exposed in vivo
to the atmosphere, altering the expression of genes (Zglinicki et al.,
2003; Parrinello et al., 2003) and causes premature senescence
(Toussaint et al., 2004). Cell culture under atmospheric oxygen
concentration must then be assessed in respect of the cellular
conditions studied, especially in studies on ageing in which ROS
strongly inﬂuence the process. T cells were shown to be particularly
sensitive to oxygen concentration (Castle, 2000). If oxygen pressure
in bloodstream is evaluated at 5% (Larbi et al., 2007), it is estimated
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hat the mean oxygen level experienced by T cells varies from 1% to
0% according to their localization (Larbi et al., 2010). Culturing T
ells at physiological oxygen concentration (5%) generates cellular
esponses closer to those detected in vivo (Atkuri et al., 2007). In
rder to detect new biomarkers of T cell ageing, we studied gene
xpression changes following activation of T cells cultured under
tmospheric or physiological oxygen pressure.
To simulate physiological oxygen tension, T cells were cultured
n a low oxygen culture platform developed within the European
roject PROTEOMAGE. This culture platform consists of three inter-
elated parts: a culture hood open to the outside (E1), a closed
ulture hood allowing to manipulate cells in a controlled oxygen
oncentration and equipped with a robot (E2) and an automated
ell incubator maintained at a controlled oxygen concentration
E3) (Fig. 2). Therefore, any cell introduced in this platform will
tay at a deﬁned oxygen concentration during the whole process,
ith no oxygen variation between handling steps (medium change,
plitting) and incubation. PBMC cells were isolated from 10 young
olunteers (35–39 years) and 10 aged volunteers (70–74 years)
ecruited in WORK PACKAGE 1. After isolation, cells were cultivated
t 5% oxygen pressure (physiological conditions) or at 21% oxygen
ressure (atmospheric conditions). T cells were then activated with
D3/CD28 dynabeads® or not, and cultivated at 5% oxygen pressure
r at 21% oxygen pressure for 72 h. Total RNA was then isolated,
etro-transcribed and PCR using speciﬁc TaqMan Low Density Array
TLDA-Applied Biosystems) were achieved. Cross-comparisons of
ene expression change between the younger vs older groups and
etween cells grown at 5% vs 21% oxygen revealed signiﬁcant differ-
nces that distinguished changes associated with age, with oxygen
ressure or both. Speciﬁc on-demand TLDA were designed to allow
nalysis of the expression of 48 genes in total including 3 house-
eeping genes (18s, B2 M and RPLP0) and 45 genes speciﬁcally
elated to the activation of T lymphocytes. The three housekeeping
enes were chosen as robust after using the Human Endogenous
ontrol Array (Applied Biosystems) that compared the expression
f 16 housekeeping genes. The genes selected appeared stable and
y referencing to the multiple internal control genes with reliable
uantiﬁcation of gene expression changes (Vandesompele et al.,
able 2
BMC samples analysed for miR  expression.
Group Explanation 
GO GEHA offspring of long living parents 
SGO  Siblings of the GEHA offspring 
RASIG  Normal population  culture platform.
2002). The further analysis of these selected genes showed that
their expression was  modulated by activation, the donor age and/or
the oxygen concentration.
4.4. microRNA arrays in biomarker discovery
MicroRNAs are small non-coding RNA molecules, 21 to 25-
nucleotides in length, mainly involved in post-transcriptional gene
regulation (translational repression, mRNA cleavage, deadenyla-
tion). Since the discovery of MicroRNAs (miRNAs) in C. elegans in
1993 (Lee et al., 1993), many efforts have been taken to further elu-
cidate the cellular function of new disclosed miRNAs. The actual
number of microRNA loci annotated in miRBase has risen from
15,172 loci in 142 species (release 16, October 2010) to 24,521 loci
in 206 species (release 20, June 2013); (Kozomara and Grifﬁths-
Jones, 2014). The number of Homo sapiens sequences listed in the
miRNAs database is 1872 (June 2014; www.mirbase.org). In 2008,
Mitchell et al. published, for the ﬁrst time, the use of miRNA-141
as biomarker distinguishing patients with prostate cancer from
healthy controls in serum or plasma. The results established the
measurement of tumor derived miRNAs in serum or plasma as
an important approach for the blood-based detection of human
cancer (Mitchell et al., 2008). In addition, circulating miRNAs can
be taken up by recipient cells, modifying the cellular behaviour
by miRNA induced silencing of target mRNAs. Actually, a huge
number of miRNAs have been reported to be speciﬁc biomark-
ers in a variety of diseases such as cancer, neurodegeneration,
diabetes and myocardial disease. In a recently published review,
Chevillet et al. summarized miRNA biomarkers for neurodegenera-
tion, cardiovascular and metabolic diseases (Chevillet et al., 2014).
The specimens used for the isolation of miRNAs included periph-
eral blood mononuclear cells (PBMCs), cerebrospinal ﬂuid, serum,
plasma, whole blood and urine, which reﬂect the wide incidence
of miRNAs in body ﬂuids. Regarding miRNA proﬁling and their use
as biomarkers of ageing in the old “healthy” population, few stud-
ies are published. The Grillari group showed that miR-17, miR-19b,
miR-20a, and miR-106a are down-regulated in human aging (Hackl
et al., 2010). In a study by ElSharawy et al. using a microarray with
# of samples Age Gender
31 68.4 ± 6.2 16 F/15 M
19 61.7 ± 8.5 9 F/19 M
140 53.8 ± 13.8 73 F/67 M
eing a
8
f
w
4
c
h
p
i
f
i
s
m
a
a
b
5
v
w
b
a
d
o
g
a
a
w
c
s
r
t
q
a
c
m
o
w
c
p
t
1
b
c
w
h
y
i
o
s
v
b
c
a
b
d
pH.R. Grifﬁths et al. / Mechanisms of Ag
63 miRNAs, the expression proﬁles obtained from blood samples
rom 15 centenarian and nonagenarian (mean of age 96.4 years)
ere compared with those of 55 younger individuals (mean age
9.5 years). Eighty miRNAs showed aging-associated expression
hanges (ElSharawy et al., 2012). In another study, in which eleven
ealthy individuals aged 20, 80 and 100 years underwent miRNA
lasma proﬁling, miR-21 was identiﬁed as a possible biomarker of
nﬂammation and thus ageing (inﬂammaging) (Olivieri et al., 2012).
In the context of the MARK-AGE subset, the primary approach
or the establishment of miRNAS as biomarkers of ageing consisted
n the isolation of total RNA from CD45+ PBMCs. Total RNA from 190
ubjects was analysed in the age range from 30 to 74 years using the
iRNA2.0 array system (Affymetrix). The subjects’ characteristics
re shown in Table 2. The false discovery cut-off was  set to <5%.
We demonstrated age- as well as group-speciﬁc miRNA healthy
geing biomarkers, which are under evaluation as new ageing
iomarkers.
. Challenges in examining large sample numbers of low
olume
Searching for biomarkers with small volumes can work well
hen high ﬁdelity ampliﬁcation of biological material is feasi-
le e.g. for DNA, mRNA and miRNA. However, high throughput
rray technology is comparative and requires the establishment of
eﬁned groups which is not consistent with the double blind nature
f the study. To address this, at the biobank, samples were decoded,
rouped by age and recoded prior to dispatch to the analysis sites
t Halle University so that the analytical sites were provided with
 subset of PBMC samples from probands of speciﬁc age ranges.
For protein analyses where ampliﬁcation of biological material
as not possible i.e. for protein biomarker discovery, the major
hallenge was in recovering speciﬁc protein from any of the given
amples. This was further complicated in cellular analyses by the
equirement to study speciﬁc T cell subsets and therefore negate
he likely contribution of age-related changes in major subset fre-
uency to any novel biomarker – i.e. to avoid a series of complex
nalyses which only determined that the ratio of CD4:CD8 was
hanged with age. To overcome this, biomarker identiﬁcation in the
embrane proteomic discovery platform (Aston) was  predicated
n collection of samples from local cohorts in the ﬁrst instance
hich enabled recovery of 5–10 times the number of CD4+ T cells
ompared to samples available in the biobank. To obtain sufﬁcient
rotein for putative biomarker discovery in CD4+ membrane pro-
eins required a minimum of T cell extraction from 40 ml  blood and
0 volunteers per group, prior to validation through the MARK-AGE
iobank.
PBMC quality and number were critical success factors for cell
ulture and miR  isolation from PBMC. Analysis was not undertaken
hen cell viability was low in case the preparation, storage and
andling of cells had contributed to alterations in miR  expression.
To validate potential biomarkers resulting from proteomic anal-
sis high throughput technology, such as ELISA and ﬂow cytometry,
s needed in order to quantitate the antigens. Even though the level
f a given antigen may  not differ in different age groups, the locali-
ation within cellular compartments or the extracellular space may
ary, thus requiring image analysis. In all of the above speciﬁc anti-
odies are needed which bind to speciﬁc epitopes in the native
onformation. Even today this remains a challenge, as commercial
vailable antibodies may  not always exhibit the speciﬁcity claimed
y the manufacture. Therefore one of the most crucial steps in
eveloping assays for validation of biomarkers remain good and
roper validation of the antibodies applied.nd Development 151 (2015) 114–121 119
6. Converting data-intensive methods to robust high
throughput analyses – experimental and statistical
challenges
Before the big-data handling approaches that are available
for protein-based antigen discovery through mass spectrometry
that are available today, during the marker-development phase of
MARK-AGE samples were pooled from multiple donors to reduce
the data complexity in plasma 2DE proteomics. The donors were
carefully selected from well-characterised groups with deﬁned
exclusion criteria as previously reported (Dunston et al., 2012).
The two populations differed only in age. An advantage of this
approach was the assumption that the differences due to age would
be greater that the inter-individual variances during within each
age population. However, there are drawbacks. First, the popula-
tions themselves do not represent the “typical” ageing seen in the
general population. This may  result in an atypically, healthy-aged
population as the comparator group against younger healthy sub-
jects. However, this approach does eliminate confounding effects
of drugs and disease on biomarker differences seen during healthy
ageing. Second, while the demographics within each of the popu-
lations were similar, there may  still be underlying major genetic
and environmental factors that affect protein expression or post-
translational modiﬁcation in a minority of the population. For these
reasons, further validation of markers identiﬁed by 2DE  was under-
taken by ELISA.
The same approach, using samples pooled from well-deﬁned,
speciﬁc-aged healthy populations, was adopted in the discovery
of cell surface marker changes. As ageing associates with differ-
ences in immune cell subsets, only membranes from CD4+ T cells
were explored to reduce potential bias from over-representation of
CD4+ compared to CD8+ cell membranes from older adults. After
identiﬁcation of novel cell surface marker antigens via a pooled-
membrane approach, the individual whole blood, optilyse-stored
samples were re-analysed to conﬁrm that any CD4+ cell surface
marker differences observed were not generated artefactually dur-
ing sample processing.
An essential validation step for newly discovered biomarkers is
to apply them within a much larger cohort of samples, however, the
greater the number of potential markers considered, the greater
the risk for false-positive discovery. An independent Work Pack-
age was established in MARK-AGE, Work Package 8: data analysis
and bioinformatics that was  based on using neural networks, cor-
relation measures and boot-strapping tools to extract a robust set
of biomarkers of human ageing and to derive a model for healthy
ageing.
7. Post-MARK-AGE high throughput technologies – future
ageing biomarker discovery tools
Robust non-gel based proteomics (commonly referred to as
‘shotgun proteomics’) offer certain beneﬁts over 2-DE and have
been used more widely in ageing biomarker discovery in vitro,
in animal models and most recently in human tissue (Dunston
and Grifﬁths, 2010; Won  et al., 2012; Shevchenko et al., 2012).
The entire complex protein mixture in samples is enzymatically
digested and followed by separation with liquid chromatography
and direct infusion into a mass spectrometer (MS). Quantitative
differences can be uncovered using a mass spectrometer capable
of MS/MS  fragmentation. For the majority of known speciﬁcally
modiﬁed proteins, second dimension MS  fragments the parent ion,
yielding one or more unique fragments for quantitation can be
applied if a known post-translation modiﬁcation is being sought. By
zooming in on one or more speciﬁed parent ion(s) and selectively
monitoring unique fragment ion transition(s), single or multiple
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eaction monitoring (SRM or MRM)  methods are established. SRM
nd MRM  offer quantitative label-free MS  approaches when MS/MS
s available. Future opportunities lie using the most advanced triple
S in hyper-reaction monitoring and SWATHTM for determining
igital ﬁngerprints based on post-acquisition SRM data mining,
owever, this methodology is very much in its infancy. Label-free
echniques have advanced and with improved mass accuracy do
ot require sample clean up to remove unreacted reporter tags, so
o not suffer loss of material in the sample preparation steps.
Isobaric tagging remains a popular approach to compare differ-
nt samples with peptides that have identical masses and chemical
roperties. Heavy and light “isotopologues” co-elute together and
re then cleaved during MS/MS. These isobaric labels have the bene-
t that they fundamentally do not interfere with peptide ionisation,
ut the conjugation processes do require signiﬁcant sample clean-
p which is often inefﬁcient, this can be a signiﬁcant issue when
ealing with valuable material such as small volumes of patient
amples. A beneﬁt of iCAT and TMT  tags is the option for a puriﬁ-
ation step by biotinylation of iCAT or antibodies to TMT  which
nables puriﬁcation using a streptavidin matrix. This extra step
emoves any unlabelled peptides which can reduce the presence
f contaminants in the sample which can interfere with peptide
onisation.
Analysis of nucleotides has been aided over the last 20 years
y the ease with which mRNA could be reverse-transcribed and
NA ampliﬁed to facilitate detection. Next generation sequenc-
ng (NGS) technologies have now accelerated to such an extent
ince the ﬁrst descriptions of their use 10 years ago, that they
re being considered in the development of clinical diagnostics
nd therapeutics (Xuan et al., 2013). One principle driver for this
s the wealth of data created and reduced costs; hundreds of
igabases of nucleotide sequence per analysis is delivered with
 reduction of sequencing cost by over ﬁve orders of magnitude
ince the approach was ﬁrst developed. The promise of this tech-
ology lies in its ability to directly sequence single DNA or RNA
olecules in biological samples without ampliﬁcation, so it there-
ore minimizes sample handling, reduces sample manipulation,
voids ampliﬁcation-induced bias, increases read length ﬂexibility
esulting in more accurate quantitation of nucleic acid molecules
ncluding alternative splice variants.
Nevertheless, targeted sequencing can yield much higher cov-
rage of genomic regions of interest while reducing the sequencing
ost and time following target-enrichment techniques such as PCR
ith array-based or solution-based hybridization. Indeed, the sys-
ematic analysis of miR, single nucleotide polymorphism and deep
equencing approaches has led to further insight into expression
hanges e.g. in the CNS (van der Brug et al., 2010).
A ﬁnal emerging area of promise in the discovery of ageing
iomarkers is the ﬁeld of metabolomics. One of the early groups
o work in this ﬁeld has suggested the resistance of ageing mus-
le to anabolic stimuli which may  underpin the loss of muscle
trength with age (Collino et al., 2014). Evidence is also emerging for
elationship between immune ageing and cell metabolism (Torrao
t al., 2014). As both the technology and data handling capabilities
mprove over the next few years, the importance of metabolism to
ealthy ageing will be better characterised.
. Conclusions
The overall objectives of this work package were to adopt new,
obust, high throughput technologies (gene expression analysis,
iRNA analysis and proteomics), to identify biomarkers from tis-
ues, cells and/or serum which deﬁne the biological age of humans.
sing high data-intensity, hypothesis-generating methods we have
rovided additional biomarkers that may  prove use in ﬁne-tuningnd Development 151 (2015) 114–121
ageing biomarkers either alone or in combination with other mark-
ers or for identifying speciﬁc age-associated diseases.
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